Repression of multiple myeloma growth and preservation of bone with combined radiotherapy and anti-angiogenic agent

Radiation Research

Volumn 173, Issue 6, 2010, Pages 809-817

  Jia, Dan ^a   Koonce, Nathan A ^a   Halakatti, Roopa ^a   Li, Xin ^b   Yaccoby, Shmuel ^b   Swain, Frances L ^a   Suva, Larry J ^a   Hennings, Leah ^a   Berridge, Marc S ^a   Apana, Scott M ^a   Mayo, Kevin ^c   Corry, Peter M ^a   Griffin, Robert J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGINEX; IMMUNOGLOBULIN LAMBDA CHAIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BONE; BONE GRAFT; BONE RADIOGRAPHY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL COUNT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; MICRO-COMPUTED TOMOGRAPHY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOCLAST; OSTEOCLAST ACTIVITY; PRIORITY JOURNAL; SCID MOUSE; TREATMENT DURATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; BONE AND BONES; BONE TRANSPLANTATION; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; HUMANS; MICE; MULTIPLE MYELOMA; PROTEIN TRANSPORT; PROTEINS; RABBITS; RADIATION-SENSITIZING AGENTS; TIME FACTORS; TUMOR BURDEN;

EID: 77953162649     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR1734.1     Document Type: Article

References (45)

1. R. A. Kyle and S. V. Rajkumar, Multiple myeloma. N. Engl. J. Med. 351, 1860-1873 (2004).
2. J. Epstein and R. Walker, Myeloma and bone disease: "the dangerous tango". Clin. Adv. Hematol. Oncol. 4, 300-306 (2006).
3. S. Thomas and R. Alexanian, Current treatment strategies for multiple myeloma. Clin. Lymphoma Myeloma 7 (Suppl. 4), S139-S144 (2007).
4. P. Jacobs, Myeloma. Dis. Mon. 36, 317-371 (1990).
5. R. A. Kyle, M. A. Gertz, T. E. Witzig, J. A. Lust, M. Q. Lacy, A. Dispenzieri, R. Fonseca, S. V. Rajkumar, J. R. Offord and P. R. Greipp, Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc. 78, 21-33 (2003).
6. B. Barlogie, E. Anaissie, F. van Rhee, M. Pineda-Roman, M. Zangari, J. Shaughnessy, J. Epstein and J. Crowley, The Arkansas approach to therapy of patients with multiple myeloma. Best Pract. Res. Clin. Haematol. 20, 761-781 (2007). (Pubitemid 350215382)
7. M. Zangari, F. van Rhee, E. Anaissie, M. Pineda-Roman, J. Haessler, J. Crowley and B. Barlogie, Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. Br. J. Haematol. 141, 433-444 (2008).
8. T. Hideshima, N. Raje, P. G. Richardson and K. C. Anderson, A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther. Clin. Risk Manag. 4, 129-136 (2008).
9. X. Armoiry, G. Aulagner and T. Facon, Lenalidomide in the treatment of multiple myeloma: a review. J. Clin. Pharm. Ther. 33, 219-226 (2008). (Pubitemid 351629761)
10. C. Jakob, J. Sterz, I. Zavrski, U. Heider, L. Kleeberg, C. Fleissner, M. Kaiser and O. Sezer, Angiogenesis in multiple myeloma. Eur. J. Cancer 42, 1581-1590 (2006).
11. G. Pruneri, M. Ponzoni, A. J. Ferreri, N. Decarli, M. Tresoldi, F. Raggi, C. Baldessari, M. Freschi, L. Baldini and G. Viale, Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br. J. Haematol. 118, 817-820 (2002).
12. W. Du, Y. Hattori, A. Hashiguchi, K. Kondoh, N. Hozumi, Y. Ikeda, M. Sakamoto, J. Hata and T. Yamada, Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment. Pathol. Int. 54, 285-294 (2004).
13. S. Kumar, R. Fonseca, A. Dispenzieri, M. Q. Lacy, J. A. Lust, T. E. Witzig, M. A. Gertz, R. A. Kyle, P. R. Greipp and S. V. Rajkumar, Bone marrow angiogenesis in multiple myeloma: effect of therapy. Br. J. Haematol. 119, 665-671 (2002).
14. T. Hideshima, D. Chauhan, K. Podar, R. L. Schlossman, P. Richardson and K. C. Anderson, Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin. Oncol. 28, 607-612 (2001).
15. W. B. Mill, Radiation therapy in multiple myeloma. Radiology 115, 175-178 (1975).
16. L. Nieuwenhuizen and D. H. Biesma, Central nervous system myelomatosis: review of the literature. Eur. J. Haematol. 80, 1-9 (2008).
17. E. J. Hall and A. J. Giaccia, Radiobiology for the Radiologist, 6th ed. Lippincott Williams & Wilkins, Philadelphia, 2005.
18. M. Garcia-Barros, F. Paris, C. Cordon-Cardo, D. Lyden, S. Rafii, A. Haimovitz-Friedman, Z. Fuks and R. Kolesnick, Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155-1159 (2003).
19. J. H. Tsai, S. Makonnen, M. Feldman, C. M. Sehgal, A. Maity and W. M. Lee, Ionizing radiation inhibits tumor neovascularization by inducing ineffective angiogenesis. Cancer Biol. Ther. 4, 1395-1400 (2005).
20. K. Niemoller, C. Jakob, U. Heider, I. Zavrski, J. Eucker, O. Kaufmann, K. Possinger and O. Sezer, Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III. J. Cancer Res. Clin. Oncol. 129, 234-238 (2003).
21. D. H. Gorski, M. A. Beckett, N. T. Jaskowiak, D. P. Calvin, H. J. Mauceri, R. M. Salloum, S. Seetharam, A. Koons, D. M. Hari and R. Weichselbaum, Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59, 3374-3378 (1999).
22. R. P. Dings, B. W. Williams, C. W. Song, A. W. Griffioen, K. H. Mayo and R. J. Griffin, Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int. J. Cancer 115, 312-319 (2005).
23. K. Yata and S. Yaccoby, The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 18, 1891-1897 (2004).
24. D. W. van der Schaft, R. P. Dings, Q. G. de Lussanet, L. I. van Eijk, A. W. Nap, R. G. Beets-Tan, J. C. Bouma-Ter Steege, J. Wagstaff, K. H. Mayo and A. W. Griffioen, The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J. 16, 1991-1993 (2002).
25. R. P. Dings, M. Loren, H. Heun, E. McNiel, A. W. Griffioen, K. H. Mayo and R. J. Griffin, Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin. Cancer Res. 13, 3395-3402 (2007).
26. X. Li, A. Pennisi, F. Zhan, J. R. Sawyer, J. D. Shaughnessy and S. Yaccoby, Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines. Br. J. Haematol. 138, 802-811 (2007).
27. S. Yaccoby, M. J. Wezeman, M. Zangari, R. Walker, M. Cottler-Fox, D. Gaddy, W. Ling, R. Saha, B. Barlogie and J. Epstein, Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica 91, 192-199 (2006).
28. S. Yaccoby, W. Ling, F. Zhan, R. Walker, B. Barlogie and J. D. Shaughnessy, Jr., Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109, 2106-2111 (2007).
29. B. Barlogie, M. Zangari, V. Bolejack, K. Hollmig, E. Anaissie, F.van Rhee, M. Pineda-Roman, A. Mohiuddin, J. Crowley and G. Tricot, Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma. Clin. Lymphoma Myeloma 6, 469-474 (2006).
30. B. Barlogie, E. Anaissie, J. Haessler, F. van Rhee, M. Pineda-Roman, K. Hollmig, Y. Alsayed, J. Epstein, J. D. Shaughnessy, Jr. and J. Crowley, Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 113, 355-359 (2008).
31. M. L. Fishel and M. R. Kelley, The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol. Aspects Med. 28, 375-395 (2007).
32. P. Martinive, F. Defresne, E. Quaghebeur, G. Daneau, N. Crokart, V. Gregoire, B. Gallez, C. Dessy and O. Feron, Impact of cyclic hypoxia on HIF-1alpha regulation in endothelial cells\new insights for anti-tumor treatments. FEBS J. 276, 509-518 (2009).
33. N. Chan, M. Milosevic and R. G. Bristow, Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncol. 3, 329-341 (2007).
34. K. Parmar, P. Mauch, J. A. Vergilio, R. Sackstein and J. D. Down, Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc. Natl. Acad. Sci. USA 104, 5431-5436 (2007).
35. K. Asosingh, H. De Raeve, M. de Ridder, G. A. Storme, A. Willems, I. Van Riet, B. Van Camp and K. Vanderkerken, Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica 90, 810-817 (2005).
36. S. V. Rajkumar, R. A. Mesa, R. Fonseca, G. Schroeder, M. F. Plevak, A. Dispenzieri, M. Q. Lacy, J. A. Lust, T. E. Witzig and P. R. Greipp, Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin. Cancer Res. 8, 2210-2216 (2002).
37. D. H. Shin, Y. S. Chun, D. S. Lee, L. E. Huang and J. W. Park, Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 111, 3131-3136 (2008).
38. J. Folkman and K. Camphausen, Cancer. What does radiotherapy do to endothelial cells? Science 293, 227-228 (2001).
39. C. M. Edwards, J. Zhuang and G. R. Mundy, The pathogenesis of the bone disease of multiple myeloma. Bone 42, 1007-1013 (2008).
40. K. Gado, G. Domjan, L. Kormos and A. Falus, Functional significance of genetic abnormalities in multiple myeloma. Haematologia 32, 191-208 (2002).
41. F. Zhan, Y. Huang, S. Colla, J. P. Stewart, I. Hanamura, S. Gupta, J. Epstein, S. Yaccoby, J. Sawyer and J. D. Shaughnessy, Jr., The molecular classification of multiple myeloma. Blood 108, 2020-2028 (2006).
42. M. Hallek, P. L. Bergsagel and K. C. Anderson, Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91, 3-21 (1998).
43. C. A. Huff and W. Matsui, Multiple myeloma cancer stem cells. J. Clin. Oncol. 26, 2895-2900 (2008).
44. W. Matsui, Q. Wang, J. P. Barber, S. Brennan, B. D. Smith, I. Borrello, I. McNiece, L. Lin, R. F. Ambinder and R. J. Jones, Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 68, 190-197 (2008).
45. J. Y. Wong, J. Rosenthal, A. Liu, T. Schultheiss, S. Forman and G. Somlo, Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation. Int. J. Radiat. Oncol. Biol. Phys. 73, 273-279 (2009).